42. Ministry of Health. Guidelines for Cervical Screening in New Zealand. Wellington: National Cervical Screening Programme, National Screening Unit, Ministry of Health, 2008. 43. Arbyn M, Snijders PJ, Meijer CJ, Berkhof J, Cuschieri K, Kocjan BJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clinical Microbiology and Infection. 2015;21(9):817-26. 44. US Food and Drug Administration. Approval letter for the cobas HPV test, Roche. Silver Spring, MD: US Food and Drug Administration, 2011. 45. Ministry of Health. National Cervical Screening Programme Policies and Standards. Section 5: providing a laboratory service. Wellington: Ministry of Health, 2015. 46. Roche Molecular Systems Inc. The Netherlands is the first country to transition its national cervical cancer screening program from Pap to primary HPV screening. 2016 [cited 2016 1 Sep]; Available from: 47. Sultana F, English DR, Simpson JA, Brotherton JML, Drennan K, Mullins R, et al. Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never- and under-screened women in Australia. BMC Cancer. 2014;14:207-. 48. Canfell K, Castle P, Caruana M, Gebski V, Darlington-Brown J, Heley S, et al. Protocol for Compass: a randomised controlled trial of primary HPV vs. cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women in Australia (version 1.2). Carlton, Victoria: Victorian Cytology Service, 2016. 49. Sultana F, Mullins R, Murphy M, English DR, Simpson JA, Drennan KT, et al. Women’s views on human papillomavirus self-sampling: focus groups to assess acceptability, invitation letters and a test kit in the Australian setting. Sexual Health. 2015;12(4):279-86.
42. Ministry of Health. Guidelines for Cervical Screening in New Zealand. Wellington: National Cervical Screening Programme, National Screening Unit, Ministry of Health, 2008. 43. Arbyn M, Snijders PJ, Meijer CJ, Berkhof J, Cuschieri K, Kocjan BJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clinical Microbiology and Infection. 2015;21(9):817-26. 44. US Food and Drug Administration. Approval letter for the cobas HPV test, Roche. Silver Spring, MD: US Food and Drug Administration, 2011. 45. Ministry of Health. National Cervical Screening Programme Policies and Standards. Section 5: providing a laboratory service. Wellington: Ministry of Health, 2015. 46. Roche Molecular Systems Inc. The Netherlands is the first country to transition its national cervical cancer screening program from Pap to primary HPV screening. 2016 [cited 2016 1 Sep]; Available from: 47. Sultana F, English DR, Simpson JA, Brotherton JML, Drennan K, Mullins R, et al. Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never- and under-screened women in Australia. BMC Cancer. 2014;14:207-. 48. Canfell K, Castle P, Caruana M, Gebski V, Darlington-Brown J, Heley S, et al. Protocol for Compass: a randomised controlled trial of primary HPV vs. cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women in Australia (version 1.2). Carlton, Victoria: Victorian Cytology Service, 2016. 49. Sultana F, Mullins R, Murphy M, English DR, Simpson JA, Drennan KT, et al. Women’s views on human papillomavirus self-sampling: focus groups to assess acceptability, invitation letters and a test kit in the Australian setting. Sexual Health. 2015;12(4):279-86.
371591-5_Protocol_ADHB%20WDHB%20HPVSS_28092016_Final%20v1_11.docx